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Abstract 20 
Objective 21 
To summarize the available evidence regarding the course of symptoms and 22 
prognostic factors in patients diagnosed with CTS and treated conservatively. Details 23 
of the protocol for this systematic review were registered on PROSPERO 24 
(CRD42013006608).  25 
Data Sources & Study Selection 26 
Through a systematic search we identified 16 cohort studies from hospital and 27 
clinical database settings, describing the course of CTS.  28 
Data Extraction 29 
Methodological bias was assessed using the Quality in Prognosis Studies (QUIPS) 30 
tool. A high risk of bias, (predominantly relating to study attrition, confounding and/or 31 
statistical analysis and reporting) was judged to be present in 8 studies. Designs 32 
showed wide variability with respect to: characteristics of the included population; 33 
definition of CTS; assessment of prognostic factors; types of interventions provided 34 
and types of outcome measures applied. This prevented pooled estimates being 35 
produced.  36 
Data Synthesis 37 
Negative outcome at 3 years follow-up of conservatively treated participants ranged 38 
from 23 – 89%. Four included studies observed the rate of surgical intervention 39 
following initial conservative management and found this to be 57-66%.  Evidence 40 
regarding factors predicting the negative outcome of no treatment or conservative 41 
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treatment was graded taking into account the number of studies evaluating the 42 
factor, the methodological quality of these studies and the consistency of the 43 
available evidence. There was 100% agreement in at least 3 or more cohorts with a 44 
medium or high risk of bias that: symptom duration; a positive Phalen’s test; and 45 
thenar wasting were associated with a negative outcome of conservative 46 
management, however not all results were statistically significant and hence the 47 
overall judgement remained inconclusive.  48 
Conclusions 49 
Results of this review should be treated with caution due to the heterogeneity of 50 
studies, and the risks of bias identified. However, the course of CTS appears 51 
variable and poor prognosis may be predicted by a longer symptom duration, a 52 
positive Phalen’s test and thenar wasting.  53 
Key words: carpal tunnel syndrome; disease management; prognosis 54 
 55 
Abbreviations 56 
CTS   carpal tunnel syndrome 57 
NSAIDS non-steroidal anti-inflammatory drugs 58 
PF  prognostic factor 59 
QUIPS Quality in Prognostic Studies  60 
 61 
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 63 
Introduction  64 
Carpal tunnel syndrome (CTS) is a chronic focal compressive neuropathy caused by 65 
the entrapment of the median nerve at the level of the carpal tunnel 1. CTS is the 66 
most common of the entrapment neuropathies, accounting for 90% of presentations 67 
2
 and is characterised by numbness, tingling, hand and arm pain and muscle 68 
dysfunction 3. Between 55–65%  of  CTS  cases  present  bilaterally4 and  the  69 
condition  can  be  associated  with hypothyroidism, diabetes, and rheumatoid 70 
arthritis, amongst others. CTS may present in late pregnancy but is usually transient. 71 
Studies in different countries have reported varying results with respect to the 72 
incidence of CTS 5.  A survey of the Skåne Health Care Register in Sweden by 73 
Atroshi et al was age-adjusted to the 2000 US standard population to allow 74 
comparison with the results of a US based survey of the Rochester Epidemiology 75 
Project 6. The estimated incidence of CTS in Sweden was reported as 324 per 76 
100,000 in women compared with 542 in the US, and in men, 166 in Sweden 77 
compared with 303 in the US 5, 6. The explanation for variation between countries is 78 
unknown, however suggested possibilities include: differences in healthcare seeking 79 
behaviour and variation in aetiological factors including occupation, diabetes and 80 
inflammatory joint disease 5.  81 
The treatment of CTS is often categorised as either surgical or conservative (non-82 
surgical). Surgical treatment is generally recommended for those with severe CTS 83 
i.e. evidence of denervation of the median nerve, whilst conservative treatments are 84 
recommended for the initial management of those who have intermittent or mild 85 
symptoms or in whom surgery is contraindicated 7. The US-standardised annual 86 
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incidence of carpal tunnel release surgery per 100,000 persons was 166 in Sweden 87 
compared with 171 in the US and, among men, 58 in Sweden compared with 96 in 88 
the US 5, 6. Examples of conservative treatment include; oral steroids, steroid 89 
injections, physical therapy, electrotherapy, night splinting and workplace 90 
alterations8. In UK primary care, steroid injections and night splinting form the 91 
mainstay of conservative treatment options, as indicated by national care pathways 92 
(for example National Institute for Health and Care Excellence Clinical Knowledge 93 
Summaries) 9, 10. Guidelines for the management of CTS by the American 94 
Association of Orthopaedic Surgeons 11 conclude that patients with more severe and 95 
prolonged CTS may not benefit from extended conservative treatment. However the 96 
authors were unable to recommend in which patients conservative treatments were 97 
unlikely to be effective 11.  98 
Cochrane systematic reviews of conservative treatments for CTS 12 have included 99 
the assessment of local corticosteroid injections 13 and splinting 7. In respect of 100 
splinting, the authors conclude that there is limited evidence that night splinting is 101 
more effective than no treatment in the short term. They do however suggest that 102 
that more research is needed on the long-term effects of this intervention 7. With 103 
regard to steroid injections, it was concluded that robust evidence demonstrates 104 
clinical improvement up to one month compared to placebo but relief beyond this 105 
time period has not yet been shown 13.   106 
With on-going clinical uncertainty regarding the most effective management strategy 107 
for CTS, there is a clear need for a greater understanding of the likely long term 108 
course of CTS symptoms (overall prognosis) of the condition and patient factors that 109 
may be associated with outcome (prognostic factors).   110 
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Outcomes and predictors of surgical outcome have been well reported in the 111 
literature, however few studies and no systematic reviews have been performed to 112 
summarise the evidence for prognosis and prognostic factors in conservatively 113 
managed disease, i.e. that which can be delivered in a primary care environment. An 114 
estimate of average prognosis is required by public health policy makers in order for 115 
the population burden of a condition to be assessed. Understanding the future 116 
outcomes of patients with a particular condition in relation to current practice and 117 
even in the absence of clinical care (the natural history) is crucial as it allows the 118 
potential impact of interventions to be more fully assessed 14. Such information is not 119 
only important when considering the potential benefits of interventions, but also in 120 
order to inform patients, clinicians and policy makers of the potential harms, 121 
variations (such as underuse, overuse, misuse) and potential impact on healthcare 122 
efficiencies 14. 123 
This systematic review and narrative synthesis initially focuses on summarising the 124 
prognosis research regarding the general course of CTS. The ‘startpoint’ of this 125 
review will be the point of diagnosis of CTS that is being treated conservatively or 126 
with no clinical treatment. The ‘endpoint’ will vary depending upon on the primary 127 
study. This synthesis therefore seeks to describe the course of CTS, being managed 128 
with either no intervention or with conservative approaches.  129 
The second part of this systematic review aims to identify predictors of long-term 130 
outcome (prognostic factors) in CTS. A prognostic factor (PF) is “any measure that, 131 
among people with a given health condition (startpoint), is associated with a 132 
subsequent clinical outcome (endpoint) 15.  Prognostic factor research thus seeks to 133 
identify the predictive value of such factors.  134 
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Research of prognostic factors aims to identify features that could potentially 135 
contribute to the development of prognostic models or represent predictors of 136 
differential treatment response, which may further contribute to a stratified care 137 
approach to a condition. Prognostic factors may also represent modifiable targets for 138 
interventions and could hence lead to the development of new management 139 
strategies through an improved understanding of disease mechanisms 15.  140 
Methods 141 
2.1 Identification and selection of the literature 142 
Details of the protocol for this systematic review were registered on PROSPERO 143 
(CRD42013006608) and can be accessed at 144 
http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42013006608#.145 
VYk_RflVhBc. Eligible publications had to report; the course of CTS symptoms 146 
(persistence / recovery or severity of pain or other symptoms), and / or the 147 
association between a potential prognostic factor and outcome as well as meeting 148 
the following eligibility criteria: 149 
• The study included adults (aged 18 years or over), diagnosed with CTS in 150 
either a clinical setting or population setting. Studies in pregnant women and 151 
in populations such as specific occupational groups were excluded 152 
• The study observed the course of CTS over at least a 6 week period in 153 
patients receiving no treatment or usual care that included conservative (non-154 
surgical) treatments. Studies reporting risk factors for onset of CTS as 155 
opposed to predictors of outcome were excluded, as were studies 156 
investigating predictors of the effectiveness of a specific treatment (which 157 
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would ideally require a review of randomised clinical trials and is planned for 158 
the future) 159 
• The design was of a longitudinal cohort study with either  prospective or 160 
retrospective data collection 161 
• There were no language restrictions and none of the research identified was 162 
only reported in abstract. 163 
A systematic, computerised search of the literature was conducted in Medline, 164 
Embase, AMED, HMIC, PsychINFO, Cinahl, Cochrane, SCI-EXPANDED and CPCI-165 
S from their inception until December 2013. The Medline search strategy can be 166 
found in Supplementary table S1.  References of all included full-text articles were 167 
hand-searched and the first 15 pages of Google Scholar results for ‘carpal tunnel 168 
syndrome’ and ‘prognosis’ were screened as a further check for relevant hits. 169 
Experts were contacted to identify any further studies or publications in the grey 170 
literature that had not been identified in the search. The titles were screened by one 171 
reviewer (CB) and abstracts were screened by two reviewers (CB and LC) and full 172 
papers of potentially eligible studies retrieved. Such papers were screened by the 173 
two reviewers independently for eligibility and included in the review if they met the 174 
pre-specified criteria.  175 
2.2 Quality assessment 176 
All selected studies were assessed independently for quality by CB and LC using the 177 
Quality in Prognosis Studies (QUIPS) tool 16. The QUIPS tool assesses bias in the 178 
six following domains: 1) study participation; 2) study attrition; 3) prognostic factor 179 
measurement; 4) outcome measurement 5) study confounding and 6) statistical 180 
analysis and reporting. Judgements of low, moderate or high risk of bias were made 181 
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for each applicable domain using descriptors recommended by Hayden et al 16. 182 
Summated scores for overall study quality are not generally recommended, however 183 
assessment of the overall risk of bias is suggested to be useful when synthesising 184 
existing evidence 16. Using suggestions from Hayden et al.,16 studies were judged to 185 
be of low overall risk of bias if all or most of the domains were judged as low risk, 186 
and studies in which all or most of the domains were judged as high risk were 187 
considered to be of high overall risk of bias. Studies with a moderate risk of bias 188 
were those with all or most of the domains being judged as moderate risk of bias. 189 
Differences between reviewers were discussed and a decision made by agreement. 190 
Agreement between reviewers (CB and LC) regarding the judgement of overall risk 191 
of bias was presented as percentage agreement. 192 
2.3 Data extraction 193 
Data were extracted by CB and checked by LC. Data extraction included details of 194 
the study setting, population demographics, diagnostic criteria of CTS used, 195 
management approaches used, prognostic factors (type of factors and how 196 
measured), outcome measures (definition and instrument used), sample size, rate of 197 
attrition and length of follow up. With regard to clinical course, the percentage of 198 
patients with a negative outcome following conservative treatment or no treatment 199 
were recorded. All reported prognostic factors were listed and measures of 200 
association with their significance levels recorded.  201 
2.4 Analysis 202 
Results regarding the course of symptoms in patients with untreated and 203 
conservatively treated CTS were summarised narratively. Pooling of results was not 204 
possible due to heterogeneity with regard to study setting, case definition, follow-up 205 
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periods and measures of outcome. We summarised findings for the reported 206 
prognostic factors by taking into account the number of studies evaluating the factor, 207 
the risk of bias of these studies and the consistency of the available evidence (as 208 
defined as significant association with the same direction). A level of evidence was 209 
defined for each factor, based on Sackett et al. 17 and Ariens et al. 18 and adapted for 210 
use with the QUIPS tool (Table 1).  211 
Results 212 
3.1 Selection of studies 213 
Figure 1 presents a flow chart of study selection. 15,572 citations were identified 214 
(6987 Medline, 6445 Embase, 197 AMED, 19 HMIC, 92 PsychINFO, 707 Cinahl, 755 215 
Cochrane, 370 SCI-EXPANDED and CPCI-S). Following the removal of duplicates 216 
and a screen of the titles, 146 abstracts were screened and 42 full text publications 217 
retrieved for further eligibility screening. 26 papers were excluded for the following 218 
reasons: one foreign language duplicate was found, 3 studies reported conditions 219 
not specific to CTS (i.e. wrist pain or unspecified entrapment neuropathies), 6 220 
studies reported outcomes in a specific population, 4 studies reported aetiology of 221 
CTS only, 6 studies reported on outcomes of specific treatments and 6 studies used 222 
a design other than that described in the selection criteria. 16 papers (reporting on 223 
16 cohorts) met all eligibility criteria and were included in the review.  224 
3.2 Study Characteristics 225 
Table 2 summarises the characteristics of the studies including the QUIPS score, 226 
study design and setting, study population, interventions used in the study, the 227 
primary outcome measure including the definition of a negative outcome, and 228 
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duration of follow-up. The table also presents the percentage of the cohort 229 
experiencing a negative outcome (e.g. surgery) of conservative or no management.  230 
One study was a retrospective follow-up study of cases identified in the Marshfield 231 
Epidemiologic Study Area, a population-based cohort 19. All other studies were 232 
based in secondary or tertiary care, of which 6 were in surgical clinics and 8 in EMG 233 
(Electromyography) laboratories. No studies were based in primary care. The case 234 
definitions used to identify CTS differed: 6 studies used clinical features only whilst 235 
the remaining 10 studies required accompanying electrophysiological abnormality. 236 
The combination of clinical characteristics used and the electrophysiological criteria 237 
also varied between studies. The interventions used in the studies included; wrist 238 
splinting (7 studies), NSAIDS (non-steroidal anti-inflammatories) (3 studies), other 239 
analgesia (2 studies), oral steroids (3 studies), local steroid injections (6 studies) and 240 
paraffin treatment (1 study). Three studies provided conservative management 241 
without specifying which mode exactly. In 4 studies, the course of (clinically) 242 
untreated CTS was observed 20-23. In some studies, parts of the cohort were treated 243 
surgically. Their specific outcomes were not included in this review.  A range of 244 
outcome measures were used: 3 studies used a surgical episode as a proxy for a 245 
negative outcome; 1 study used the Quickdash score; 5 used measures of global 246 
improvement; 2 used a change in symptom and function severity scores; 1 used the 247 
Historic and Objective Scale 24; 1 used work absence; 2 observed 248 
electrophysiological changes and 1 used absence of clinical contact as an indicator 249 
of recovery. The follow-up periods ranged from 12 weeks to 10 years. 250 
 251 
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3.3 Methodological quality 252 
The results of the quality assessment are presented in Table 3. In 4 studies, 253 
investigating course of CTS symptoms only, the prognostic factor domain was not 254 
assessed.  The percentage agreement between authors CB and LC, with regard to 255 
judgement of the overall risk of bias was 75% and 100% following discussion.  256 
Further adjudication was therefore not required.  257 
Eight studies were judged to have a moderate risk of bias and 8 to have a high risk 258 
of bias. The domains that carried a particularly high risk of bias across all studies 259 
were: study attrition (12 studies); study confounding (10 studies) and statistical 260 
analysis and reporting (9 studies). Study attrition tended to be at high risk of bias as 261 
the response rates in several studies were low (see table 3), attempts to collect 262 
information on participants who dropped out was often lacking, reasons for loss to 263 
follow-up were rarely provided and differences between those lost to follow-up and 264 
those actively followed up were not frequently compared. Study confounding was 265 
also a frequent finding largely due to the fact that not all potential confounders were 266 
appropriately accounted for and hence the observed associations of the potential 267 
prognostic factors with outcome were likely to be at least partly explained by other 268 
(unmeasured) factors. This was particularly true in studies using retrospectively 269 
collected data.  Statistical analysis and reporting was commonly identified as being 270 
of high risk of bias as presentation of the data was frequently insufficient and in 271 
some studies selective reporting of results was evident.  272 
3.4 Course of carpal tunnel syndrome 273 
For each included study, Table 2 describes results regarding the course of CTS in 274 
conservatively treated or untreated patients by describing the proportion of patients 275 
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who experience a negative outcome, the definition of which varied between studies 276 
(i.e. persisting or worsening symptoms, progression to surgery, or work absence due 277 
to CTS). Table 4 further summarises results regarding the course of CTS in terms of 278 
the percentage of patients reporting a negative outcome for different follow-up time 279 
points.  280 
4 studies examined the course of untreated CTS 20-23. OrizCorredor et al observed 281 
that of 132 patients with untreated CTS over a 2 year period, 23.5% showed a 282 
deterioration in the HiOb score but most cases did not show an electrophysiological 283 
deterioration (89 remained the same, 33 recovered and 10 deteriorated. Only 1 284 
patient had both an electrophysiological and clinical deterioration22. Padua 1998 et al 285 
reported whether the clinical outcome was unchanged or worse in groups of patients 286 
with different electrophysiological classifications. They found the clinical outcome 287 
was worse in 50% of patients with negative electrophysiology, 27.5% with moderate 288 
studies and 50% of extreme studies 20. Padua 2001 et al further observed the 289 
electrophysiological, symptomatic, functional, HiOb and pain changes in patients 290 
with CTS. They reported that 16%, 21%, 16%, 32% and 12% of patients in each of 291 
these outcome areas worsened 21, whilst 27%, 34%, 23%, 23% and 26% of patients 292 
improved 21. Resende et al presented the change in electrophysiological measures 293 
and accompanying change in symptoms over a 4 to 9 year periods and found that 294 
25% of patients had a marked improvement in electrophysiological outcome (100% 295 
of whom had improvement in terms of symptoms); 15% showed slight improvement 296 
(of whom 33% had worsening of symptoms); 50% showed no significant change (of 297 
whom 50% had worsening in terms of symptoms) and 10% had a worsening of 298 
electrophysiological measurements (of whom 50% had a worsening of clinical 299 
symptoms) 23. In summary, 32 - 58% of participants receiving no treatment were 300 
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reported to have a negative outcome at 12 months follow-up in two studies 20, 21, both 301 
of which were of moderate risk of bias. The two further studies reporting at 3 and 10 302 
years were at high risk of bias and reported a negative outcome in 23.4%22 and 50% 303 
23
.  304 
In the 9 cohorts receiving conservative treatment: 68.5% - 75% of patients were 305 
reported to have a negative outcome within 3 months follow-up 25, 26; 82% within 6 306 
months 27; 23 – 89% within 3 years 19, 28-31  and 22 – 24% within 10 years 28, 32. A 307 
wide variation in findings was noted according to risk of bias, with studies of a 308 
moderate risk of bias appearing to show lower percentages of patients with a 309 
negative outcome (e.g. 23 – 68% at 3 years 19, 28-30), compared to studies of high risk 310 
of bias (82% at 6 months27 and 89% at 3 years31). Four studies used a surgical 311 
episode as a marker of negative outcome of conservative management 27, 33-35. A 312 
range of 57% to 66% of patients were observed to receive surgery following 313 
conservative management over a period of between 1 and 3 years 27, 33-35. In 314 
summary, the reported course of conservatively managed CTS is highly variable but 315 
symptoms do improve over time.  316 
3.5 Prognostic factors predicting negative outcome of carpal tunnel syndrome 317 
Eleven of the studies presented data on the association between potential prognostic 318 
factors and a negative outcome of conservatively managed CTS. 319 
Table 5 presents potential prognostic factors observed in the studies and reported 320 
associations. Not all studies presented estimates of associations with confidence 321 
intervals. Some presented P values only; some simply reported a finding as non-322 
significant. Therefore, the number of studies investigating each association, the 323 
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number of studies of moderate or high risk of bias (none were of low risk) and the 324 
number showing an association (direction and significance) are summarised.  325 
In total 39 potential prognostic factors were identified from the studies. All of these 326 
were found to have inconclusive levels of evidence of an association with a negative 327 
outcome. This was due to inconsistencies in study findings, non-significant results, 328 
low numbers of studies investigating each factor and the moderate to high risk of 329 
bias of the studies included.  330 
Discussion 331 
This study is the first systematic review of the prognosis of conservatively managed 332 
CTS. A substantial amount of heterogeneity exists in terms of study setting, case 333 
definition, follow-up periods and measures of outcome between the included studies, 334 
which prevented meta-analysis from being conducted. A best evidence synthesis 335 
was therefore presented.  336 
4.1 Course of carpal tunnel syndrome 337 
Four studies observed the course of untreated CTS 20-23, which is helpful when 338 
considering the need for or impact of treatment. These studies suggest that a 339 
proportion (28% - 62%) 20-23 of patients will recover or not deteriorate further in the 340 
absence of treatment and hence a certain period of ‘watchful waiting’ (not clearly 341 
defined by the available evidence) may be considered clinically when discussing 342 
treatment options with patients. When considering potential mechanisms for 343 
recovery (not including mechanisms of treatment) Padua et al 1998 suggest that 344 
certain undefined CTS cases are self-limiting due to a process of neural adaption, 345 
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whereby the functional relationship between the nerve and the carpal tunnel adapts 346 
over time20.  347 
Due to outcomes being measured at discrete time points by each study, it was not 348 
possible to provide a cumulative percentage of patients recovering in each period 349 
and so provide clearer information about what is happening to patients with CTS 350 
over time. Table 4 does however show that a proportion of patients can be observed 351 
to have deteriorated from baseline at any point between 3 months and 10 years, 352 
suggesting that the course of CTS is likely to be highly variable. It is possible that the 353 
studies with longer follow up periods may be representative of patients who improve 354 
and relapse over time, but as none of the studies were designed to observe the 355 
longitudinal course of CTS (i.e. at a week-to-week or month-to-month level), such a 356 
symptom course could not be illustrated by this review.  357 
With regard to symptom relapse, only one study31 specifically addressed this issue. 358 
Goodwill et al reported that 85% of patients initially responding to conservative 359 
treatment approaches relapsed within 1 to 4 years31. The possibility of future relapse 360 
therefore puts into question the observations of all studies conducted over a shorter 361 
time frame. A further consideration is that a recurrence of symptoms following a 362 
conservative treatment which then responds to a further episode of conservative 363 
management (if deemed clinically appropriate), may not necessarily represent 364 
treatment failure. However, longitudinal data which may describe this phenomenon 365 
was not available, again emphasising the importance of long-term studies with 366 
repeated assessment of symptoms in patients with CTS.     367 
The observed between-study variability may be partially explained by substantial 368 
differences in study setting, study design, case definitions, interventions (the 369 
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effectiveness of which cannot be compared between studies), and outcomes used 370 
but possibly also by differences in patient or disease factors (potential prognostic 371 
factors) between studies. 372 
4.2 Prognostic factors predicting negative outcome of conservatively managed 373 
carpal tunnel syndrome 374 
Due to inconsistencies between study findings and the lack of studies with a low risk 375 
of bias, it was not possible to identify conclusive evidence for any of the factors 376 
reported by individual studies to predict a negative outcome of conservative 377 
management.  378 
There was however 100% agreement in at least 3 or more cohorts with a medium or 379 
high risk of bias that: symptom duration; a positive Phalen’s test; and thenar wasting 380 
were associated with a negative outcome of conservative management, however not 381 
all results were statistically significant and hence the overall judgement remained 382 
inconclusive.  383 
Due to a lack of robustness in design and conduct of most of the included studies, 384 
the overall body of evidence identified was felt to be of moderate and high risk of 385 
bias. This limited whether the synthesised evidence could be considered as 386 
conclusive and as such evidence regarding the prognosis of untreated and 387 
conservatively treated CTS remains weak.  To improve future research key 388 
recommendations would include identifying patients with CTS at baseline using a 389 
robust case definition of the condition. Patients should be followed up for a 390 
prolonged period (over 3 years), preferably at a number of time points using a 391 
clinically meaningful, valid and reliable outcome measure. This would allow a 392 
longitudinal picture of CTS to be mapped.  Attempts could be made to reduce 393 
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attrition or better describe the risk of attrition bias by collecting information from non-394 
responders and to provide a description and reason for any loss to follow up. Ideally, 395 
all potential prognostic factors should be included and measured at baseline using 396 
valid and reliable measures 16. 397 
To capture the start point of the condition and its earliest management, it would be 398 
beneficial to set such a study in primary care, where it is likely most patients present 399 
initially with their symptoms and commence treatment.  400 
4.3 Limitations 401 
We searched electronic databases considered to be important and relevant to the 402 
topic. Titles were screened by one person due to the significant number; hence 403 
human error may have led to some titles being missed. Studies not included in 404 
databases and not identified through reference checking, Google Scholar and expert 405 
advice may have been overlooked, such as unpublished cohort studies. As the 406 
review did not find strong evidence for any of the prognostic factors, it is unlikely that 407 
further unpublished material would have strongly influenced our conclusions. The 408 
review focussed on studies observing the course of symptoms in patients being 409 
treated conservatively for CTS but excluded cohorts being allocated specific 410 
treatments. Predictors of differential treatment response (moderators) are best 411 
identified by randomised trials and as such a further systematic review of these 412 
studies is planned.  413 
Results of studies presenting only descriptive results and P-values were included in 414 
the review, without any risk estimates. All evidence found could therefore be 415 
included but there is a possibility that the lack of statistical significance was due to 416 
small sample sizes and hence represent a lack of evidence for some of the 417 
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prognostic factors rather than a genuine absence of association. Future prognosis 418 
research in the area of CTS should therefore ensure that estimates of associations 419 
with outcome are adequately reported and that the study population is of adequate 420 
sample size to investigate the hypothesised associations with outcome.   421 
The unit of analysis differed between studies i.e. some analysed outcomes at patient 422 
level (not necessarily taking into account the laterality of the condition); whilst others 423 
analysed outcomes at wrist level (i.e. patients with bilateral symptoms may be 424 
included as 2 cases, not taking dependence of outcomes within individuals into 425 
account). Issues relating to the statistical analysis of bilateral CTS has been 426 
discussed at length for clinical trials by Page et al 36. A unit-of-analysis error, which 427 
may give rise to overly narrow confidence intervals and small P values, may occur 428 
when data is analysed on the basis of the number of wrists without adjustment for 429 
non-independence 36. Such an error may also occur in prognosis research, including 430 
the reviewed studies, and be a further source of bias. Future prognostic studies 431 
should, where possible, take into consideration this risk of bias in their design and 432 
analysis plan. 433 
4.4 Implications for clinical practice 434 
Patients presenting with CTS can be informed of the possibility of recovery with no 435 
treatment or conservative treatment i.e. that they will not require surgery, however 436 
factors which help to predict their likelihood of falling into this group have not been 437 
robustly determined. Increasing symptom duration, positive Phalen’s test and thenar 438 
atrophy are likely to be prognostic factors of poor outcome of conservatively 439 
managed CTS but need confirmation in further well-designed prognostic studies. The 440 
review did not identify electrophysiological severity as a significant predictor of a 441 
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negative outcome of conservative management. This may have implications for 442 
services which ration surgery to patients with more severe results and suggest other 443 
factors should be taken into consideration alongside laboratory investigations. 444 
Conclusion  445 
In this review we found useful descriptions of both the course of untreated CTS and 446 
that of conservatively managed CTS. Although none of the studies were of low risk 447 
of bias, studies of moderate and high risk of bias showed a widely ranging course of 448 
symptoms, with 23 – 89% of participants reporting negative outcome at 3 years 449 
follow-up. We found no consistent evidence to support factors which predict future 450 
outcome and may help to explain the wide variability in the course of symptoms.  451 
There is likely to be an optimum time by which conservative management should be 452 
deemed to have failed and surgical intervention considered, in order to prevent long 453 
term harm, although this point has not been clearly determined nor is it clearly 454 
possible to predict which patients may be included in this group.  455 
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Table 1 Levels of evidence for prognostic factors 17, 18 
Level of evidence  
Strong Consistent findings (≥ 75%) in at least 2 cohorts with a 
low risk of bias 
Moderate Consistent findings (≥ 75%) in one cohort with a low risk 
of bias and at least one cohort with a moderate/high risk 
of bias 
Weak Findings of one cohort with a low risk of bias or 
consistent findings (≥ 75%) in at least 3 or more cohorts 
with a moderate / high risk of bias 
Inconclusive Inconsistent findings irrespective of study quality, or less 
than 3 cohorts with a moderate / high risk of bias 
No evidence No data presented 
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Table 2 Summary of study characteristics and results regarding the course of symptoms of prognostic cohort studies in carpal 1 
tunnel syndrome 2 
Author (Year) Risk of bias 
(QUIPS score) 
Study 
population 
Interventions 
provided to 
entire cohort 
Primary 
outcome 
measure / 
duration follow 
- up 
Measure of 
negative 
outcome of 
conservative 
management 
Proportion of 
patients 
treated 
conservatively 
experiencing  
negative 
outcome 
Treated populations: prospective cohort studies 
  
Boyd et al.  
200533 
High  Setting: tertiary 
hand and 
upper limb 
Splint: all wrists 
 
Surgery: 27 
No surgery 
versus surgery 
by 6 months 
Progression to 
surgery 
57% of wrists 
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Canada 
centre 
CTS diagnosis: 
clinical findings 
and 
electrophysiolo
gical 
abnormality  
 
68% female 
Mean age: 
49.3 years 
 
N=25 patients 
(57%) wrists  
 
 
 
12 weeks, with 
an option to 
continue 
follow-up >6 
months 
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(47 wrists)  
Drop-out = 
17% 
 
Duckworth et 
al. 201334 
 
Scotland 
Moderate  Setting: hand 
clinic 
CTS diagnosis: 
clinical findings 
and 
electrophysiolo
gical 
abnormality   
 
Splint: all 
patients 
 
Injection: 150 
(55%) (of 
whom 38 had 
surgery) 
 
Surgery: 122 
QuickDA H 
Score 
 
1 year 
Progression to 
surgery 
58% of patients 
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67% female 
Mean age: 
males 57 (s.d. 
14) years; 
females 54 
(s.d. 14) years 
 
N=275 patients 
Drop-out = 
28% 
 
(44%) patients 
 
No further 
treatment: 3 
(1%) patients 
 
Goodwill.  
196531 
High  Setting: EMG 
laboratory 
Splint: 98 
(63%) wrists 
Judgement 
made at follow-
up: cured, 
Evidence of 
symptoms 
Following 
steroid 
injection: 88% 
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England 
CTS diagnosis: 
paraesthesia 
and pain with 
electrophysiolo
gical 
abnormality 
 
93% female 
Age bands: 
30-39: 7 
40-49: 19 
50-59: 39 
60-69: 18 
 
Injection: 58 
(37%) wrists 
 
Surgery: 55 
(35%) wrists 
 
 
 
temporary 
relief or no 
relief 
 
1 - 3 years 
(average 14 
months) 
of patients 
Following 
splinting: 89% 
of patients 
Following 
surgery: 5% of 
patients 
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70+: 13 
patients 
 
N=96 patients 
(155 wrists)  
Drop-out = 0% 
 
Kaplan, 
Glickel & 
Eaton.  
199027 
 
USA 
High  Setting: hand 
clinic 
CTS diagnosis: 
presence of 
pain or 
paraesthesia 
and clinical 
Splint: ‘most 
patients’ 
 
Non-steroidal 
anti-
inflammatory: 
Success of 
therapy as 
defined by 
absence of 
symptoms for > 
6 months 
Evidence of 
symptoms after 
6 months 
Progression to 
surgery 
82% of wrists 
 
 
66% of wrists 
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findings (thenar 
atrophy, 
altered 
sensation or 
Phalen’s sign)  
 
75% female 
Mean age 55 
years 
 
N = 229 
patients (331 
wrists)  
Drop-out = 
149 (65.2%) 
patients 
 
Oral steroid: 61 
(26.8%) 
patients 
 
Steroid 
injection: 38 
(16.4%) 
patients 
 
 
Minimum of 6 
months or until 
had surgical 
release 
(average 15.4 
months) 
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12% 
 
Katz et al.  
1998 a30 
 
USA 
Moderate  Setting: 
surgical clinics  
CTS diagnosis: 
paraesthesia 
involving at 
least 2 digits 
(thumb or 
index, middle 
or ring fingers) 
and symptom 
duration of at 
least 1 month 
Non-surgical 
cohort: 34 
patients 
received 
surgery at less 
than 3 months 
and were not 
included in 
analyses 
 
By 30 months: 
Splint: 76 
Change in 
status in 
symptom 
severity, 
functional 
limitations and 
health status 
were recorded 
over time. 
Associations 
were measured 
for patients 
crossing 
Would not be 
happy to live 
the rest of their 
lives with 
symptoms 
60% of patients 
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74% female 
Surgical 
cohort: >55yr 
mean age 68.0 
years (sd 9.1); 
<55yr 
compensation 
non recipient 
42.0 years (sd 
7.3); 
compensation 
recipient mean 
age 39.0 years 
(sd 8.1). 
(94%) patients 
 
Injection: 36 
(44%) patients 
 
Physical or 
occupational 
therapist: all 
 
between non-
surgical to 
surgical 
cohorts after > 
3 months. 
 
Follow up took 
place at 6, 18 
and 30 months 
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Non-surgical 
cohort >55yr 
mean age 64.0 
years (sd 7.0); 
compensation 
non-recipient 
mean age 41.0 
(sd 8.9); 
compensation 
recipient mean 
age 37.0 years 
(sd 8.8) 
 
N = 297 
patients 
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Drop-out = 
31% 
 
Kiylioglu et al.  
200926 
 
Turkey 
Moderate  Setting: EMG 
laboratory  
CTS diagnosis:  
clinical 
findings, 
supported by 
electrophysiolo
gical 
abnormality.  
 
90% female 
Treatment 
methods not 
controlled or 
standardised 
 
‘Rehabilitation’: 
patients  
treated with 
splints, paraffin 
treatments and 
/ or oral non-
Symptom 
severity score 
and functional 
status (Boston 
questionnaire 
translated into 
Turkish) 
 
Patients were 
followed up in 
the early 
Percentage 
improvement in 
symptom 
severity scale 
 
 
Percentage 
improvement in 
function 
severity scale 
Rehabilitation 
82 
Surgery          
77 
Untreated       
25 
 
 
Rehabilitation 
73 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Diabetic 
rehabilitation 
group mean 
age 59.3 years 
(sd 7.4); 
diabetic 
untreated 
group mean 
age 54.6 (sd 
11.1); 
idiopathic 
rehabilitation 
group mean 
age 47.8 years 
(sd 9.9); 
idiopathic 
steroidal anti-
inflammatories  
follow-up 
period (3-5 
months) and 
late follow up 
period (6-12 
months) 
 
Surgery          
85 
Untreated       
17 
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surgery group 
mean age 49.2 
(sd 9.8) 
 
N = 42 patients 
(80 wrists)  
Drop-out = 0 
(assumed) 
 
Treated populations: retrospective cohort studies 
Kouyoumdjian 
et al. 200332 
 
High  Setting: EMG 
laboratory  
CTS diagnosis: 
Surgery: 147 
(66%) wrists 
 
General patient 
satisfaction: 
complete relief; 
improved 
Symptoms 
unchanged or 
worse 
23.7% of wrists 
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Brazil symptoms 
including hand 
paraesthesia, 
numbness and 
pain mainly at 
night. 
 
95.8% female 
Surgical cure 
group mean 
age 46 years 
(range 24 – 
70); 
unchanged / 
worse group 44 
Non-surgical 
(splint, local 
injection, 
medication and 
others): 75 
(34%) wrists 
“much better”; 
improved 
“little”; 
unchanged; 
worsened 
 
Poorly 
recorded. 
Between 5-10 
years, (mean 
5.9 years 
following 
surgery) 
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years (range 
39 – 58); non-
surgical cure 
group mean 
age 61 years 
(range 48 – 
79); worse 
group 50 years 
(range 30 – 83) 
 
N = 165 
patients (222 
wrists) 
Drop-out = 
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69% 
 
Lian, Urkunde 
& Verma.  
200625 
 
Singapore 
High  Setting: EMG 
laboratory 
CTS diagnosis:  
clinical history 
and 
examination, 
confirmed 
using AAEM 
criteria and 
additional 
testing if this 
was normal 
Conservative 
management: 
88 (77%) 
patients 
 
Surgery: 27 
(23%) patients 
Clinician 
review of 
medical 
records and 
decision made 
as to category: 
resolved; 
improved; 
same; worse 
 
Follow up took 
place at 3 and 
Symptoms 
unchanged or 
worse 
68.5% of 
patients 
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81.3% female 
Mean age 53.6 
years 
 
N = 115  
Drop-out 14% 
 
6 months 
(limited data 
available) 
Miranda, 
Asaad & 
Cerovac.  
201335 
High  Setting: plastic 
surgery clinic 
CTS diagnosis: 
based on 
clinical 
Injection: 66 
(49%) patients 
 
Surgery: 68 
Symptom relief 
and  / or 
surgery 
 
22.5 +/- 0.5 
Progression to 
surgery 
62% of patients 
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UK 
symptoms  
 
Gender not 
reported 
Mean age 56 
years (sd 3) 
 
N = 134  
Drop-out 10% 
 
(51%) patients  months 
Muhlau, Both 
& Kunath.  
Moderate  Setting: EMG 
laboratory   
CTS diagnosis: 
Conservative 
management: 
72 (48%) wrists 
An overall 
categorisation 
was made at 
No evidence of 
cure 
68% of patients 
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198428 
 
Germany 
distal motor 
latency was 
>4.7ms  
 
Gender and 
age not 
reported 
 
N = 157 (214 
wrists)  
Drop-out 38% 
 
Surgery: 112 
(52%) wrists 
follow up: 
cured; clear 
improvement; 
slight 
improvement; 
unchanged 
findings; further 
deterioration. 
These were 
then 
dichotomised 
so that groups 
1 and 2 = 
cured and 3,4 
and 5 = not 
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cured.  
 
Follow up was 
at least 2 years 
and defined as 
when the 
patient had 
reached a 
‘steady state’ 
 
Treated populations: Retrospective follow-up study of a population-based case series 
DeStefano, 
Nordstrom & 
Vierkant.  
Moderate  Setting: 
patients 
identified from 
Analgesia: 143 
(34%) patients 
No surgery 
versus surgery 
and resolution 
Evidence of 
symptoms 
1 month: 75% 
of patients 
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199719 
 
USA 
the Marshfield 
Epidemiologic 
Study Area  
CTS diagnosis: 
ICD-9-CM code 
354.0 and 
evidence of a 
clinical and / or 
electrophysiolo
gical 
abnormality in 
the records.  
 
62% female 
 
Non-steroidal 
anti-
inflammatories: 
132 (31%) 
patients 
 
Injection: 6 
(1%) patients 
 
Splint: 295 
(69%) patients 
 
of symptoms 
 
Median follow- 
up 1979 - 
1983: 12.0 
years (5 and 
95th 
percentiles:10.
0 and 14.8 
respectively). 
184-1988: 7.3 
years (5.0-9.8) 
 
2 years:  40% 
8 years:  22% 
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Mean age 62 
years 
 
N= 425  
Drop-out 0%  
 
Surgery: 198 
(47%) patients 
  
Treated populations: Secondary analysis of Katz et al.1998 a 
Katz et al  
1998 b29 
 
USA 
Moderate  Setting: 
surgical clinics  
CTS diagnosis: 
paraesthesia 
involving at 
least 2 digits 
Surgery: 179 
(71%) patients  
Out of work at 
18 months 
 
Questionnaires 
were 
completed at 6, 
Work absence 
at 18 months, 
due to CTS 
23% of patients 
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(thumb or 
index, middle 
or ring fingers) 
and symptom 
duration of at 
least 1 month 
 
72% female 
Mean age 43 
years (sd 11) 
 
N= 253 
patients 
Drop-out =  
18 and 30m 
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20% 
 
Untreated populations: prospective cohort studies 
OrtizCorredor 
et al. 200822 
 
Columbia 
High  Setting: EMG 
laboratory  
CTS diagnosis:  
as per Rempel 
et al  
 
81.1% female 
Mean age 48.8 
years (sd 10.2) 
 
The course of 
untreated CTS 
was observed 
The Historic 
and Objective 
Scale (HiOb) 
was used as 
the clinical 
classification. 
The 
electrophysiolo
gical 
classification 
was according 
to Padua 1997 
Deterioration in 
the Historic 
and Objective 
Scale 
23.4% of 
patients 
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N = 132 
patients 
Not possible to 
determine 
drop-out 
(mild; 
moderate A; 
moderate B; 
Severe; 
Extreme) 
 
24.2 months 
(sd 4.2) 
Padua et al.  
199820 
 
Italy  
Moderate  Setting: EMG 
laboratory  
CTS diagnosis:  
based on 
neurophysiolog
ical evaluation 
The course of 
untreated CTS 
was observed 
Patient 
reported global 
improvement 
scale: stable, 
worse, 
improved 
 
 
Clinical 
outcome: 
unchanged 
Neurophysiolog
ical 
classification 
Negative   50% 
Minimal     38% 
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graded: 
negative, 
minimal, mild, 
moderate, 
severe and 
extreme 
(Padua et al).  
 
78.8% female 
Mean age 48.8 
years (sd 10.2) 
 
N = 80  
 
Neurophysiolo
gical 
classification: 
negative, 
minimal, mild, 
moderate, 
severe, 
extreme 
 
11.6 months 
(range 5-23) 
 
 
 
 
 
Clinical 
outcome: 
worse 
Mild          15% 
Moderate  
27.5% 
Severe      0% 
Extreme    50% 
Negative   50% 
Minimal     31% 
Mild          58% 
Moderate 45% 
Severe     20% 
Extreme   0% 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Drop-out 84% 
Padua et al.  
200121 
 
Italy 
Moderate  Setting: EMG 
laboratory  
CTS diagnosis:  
based on 
clinical 
diagnostic 
criteria 
proposed by 
the American 
Academy of 
Neurology and 
the American 
Association of 
Electrodiagnost
The course of 
untreated CTS 
was observed 
Electrophysiolo
gical changes, 
patient 
reported 
changes and 
clinical 
changes were 
used to 
describe if 
patients had: 
improved, 
remained 
stationary or 
worsened. 
Neurophysiolo
gic class 
 
 
Symptoms 
 
 
Function 
 
 
Historic and 
Stationary      
57% 
Worsening     
16% 
 
Stationary      
45% 
Worsening     
21% 
 
Stationary      
61% 
M
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ic Medicine 
 
82% female 
Mean age 52.0 
years (sd 13.4) 
 
N = 202 (267 
wrists) with a 
further 62 (87 
wrists) re-
evaluated by 
phone  
Drop-out 34% 
 
10 - 15 months 
objective scale 
 
Pain 
Worsening     
16% 
 
Stationary      
46% 
Worsening     
32% 
 
Stationary      
62% 
Worsening     
12% 
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Untreated populations: retrospective cohort studies 
Resende et al.  
200323 
 
Brazil 
High  Setting: EMG 
laboratory  
CTS diagnosis:  
clinical 
findings, 
supported by 
electrophysiolo
gical 
abnormality 
 
Patients in an 
EMG lab with a 
The course of 
untreated CTS 
was observed 
Clinical and 
electrophysiolo
gical changes 
were observed. 
 
4 – 9 years 
Conduction 
studies 
 
 
 
 
Marked 
improvement  
25% (of which 
100% had          
improvement in 
symptoms) 
Slight  
improvement    
15% (of which 
33% had 
worsening of 
clinical 
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diagnosis of 
CTS based on.  
 
N=12  
Drop-out not 
possible to 
determine  
symptoms) 
No significant 
change  50% 
(of which 50% 
had worsening 
of clinical 
symptoms) 
Worsening                   
10% (of which 
50% had 
worsening of 
clinical 
symptoms) 
 3 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Table 3 Results of the methodological assessment of prognostic cohort studies on CTS 
Author (year) 1. Study 
Participation 
2. Study 
Attrition 
3. Prognostic 
Factor 
Measurement 
4. Outcome 
Measurement 
5. Study 
Confounding 
6. 
Statistical 
Analysis 
and 
Reporting 
Overall 
Risk of 
bias 
Studies including an analysis of prognostic factors 
 
Boyd  et al. 
200533 
High High Moderate Moderate Moderate High High 
DeStefano, 
Nordstrom & 
Vierkant. 
199719 
Low Moderate Moderate Moderate Moderate Moderate Moderate 
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Duckworth et 
al. 201334 
Moderate High Moderate Moderate High Low Moderate 
Goodwill. 
196531 
High High High High High High High 
Kaplan, 
Glickel & 
Eaton. 199027 
High High High High High High High 
Katz et al. 
1998a30 
Low Moderate Moderate Moderate Low High Moderate 
Katz et al 
1998b29 
Low High Moderate Low High Low Moderate 
Kiylioglu et al. 
200926 
Moderate High Moderate Moderate Moderate High Moderate 
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Kouyoumdjian 
et al. 200332 
Moderate High Moderate Moderate High High High 
Muhlau, Both 
& Kunath. 
198428 
Moderate High Low Moderate Moderate Low Moderate 
Padua et al. 
200121 
Low Moderate Low Moderate Moderate Moderate Moderate 
Studies observing the course of CTS only (with no analysis of prognostic factors) 
 
Lian, Urkunde 
& Verma. 
200625 
High High Not applicable High High High High 
Miranda, 
Asaad & 
High High Not applicable High High High High 
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Cerovac. 
201335 
OrtizCorredor 
et al. 200822 
Moderate Moderate Not applicable Low High High High 
Padua et al. 
199820 
High High Not applicable Low High Low Moderate 
Resende et al. 
200323 
High High Not applicable High High Moderate High 
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Table 4 Course of carpal tunnel syndrome in conservatively treated or untreated patients (percentages not cumulative) 
Number 
of 
studies 
Sample 
size 
range 
% of cases 
reporting 
deterioration 
within 3 
months 
% of cases 
reporting 
deterioration 
within 6 
months 
% of cases 
reporting 
deterioration 
within 12 
months 
% of cases 
reporting 
deterioration 
within 3 
years 
% of cases 
reporting 
deterioration 
within 5 
years 
% of cases 
reporting 
deterioration 
within 15 
years 
Untreated cases 
4 20-23 12 – 
344  
  32 - 58 23.4  50 
Studies observing cases receiving surgery as a consequence of conservative management failure (% of 
patients receiving surgery NOT outcome of surgery) 
4 27, 33-
35
 
47 - 
331 
 57 58 62 - 66   
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Studies of conservatively managed patients reporting other definitions of negative outcome 
9 19, 25-
32
 
80 - 
425 
68.5 - 75 82 % 
improvement 
of up to 82% 
* 
 
23 - 89  22 - 23.7 
The percentages shown are not cumulative as it cannot be assumed that patients reporting a change in 
symptoms at 6 months, would not have reported something different at an earlier or later date if the study 
had provided them with such opportunity 
 
• % change provided in positive direction 
26
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Table 5 Prognostic factors and strength of association for an unfavourable outcome of carpal tunnel 
syndrome in patients who are conservatively treated or untreated 
Prognostic 
factor 
Direction of 
association 
and 
significance 
  
Risk of bias 
(number of 
studies) 
 
Number and 
% of studies 
demonstratin
g predictive 
association 
with a 
negative 
outcome 
(statistically 
significant) 
Level of 
evidence 
Demographic 
characteristics 
    
Female gender  +* 34 
+  19 
0 28,30, 29 
027 
Moderate (5) 
 
 
High (1) 
2/6: 33% 
(1/6: 17 %) 
Inconclusive 
Increasing age 
(group not 
otherwise 
specified or >50 
years) 
+* 21,29 Moderate (7) 3/10: 30 % 
(3/10: 30 %) 
Inconclusive 
0 30 , 28 
-*
34
, 
26
, 
19
 
+* 27 
-*
33
 
-
32
 
High (3) 
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Obesity + 19 
-* 
26
 
Moderate (2) 1/2: 50% 
(0/2: 0%) 
Inconclusive 
Litigation +* 29 Moderate (3) 1/3: 33% 
(1/3: 33%) 
Inconclusive 
0 30, 28 
Deprivation 
quintile 
- 
34
 Moderate (1) 0/1: 0 % Inconclusive 
Vibration tool 
use 
- 
34
 Moderate (1) 0/1: 0 % Inconclusive 
Occupation 
status 
+*29 Moderate (1) (1/1: 100)% Inconclusive 
Smoking +34 Moderate (1) 1/1: 100% 
(0/1: 0%) 
Inconclusive 
Comorbidity     
Diabetes +* 26 Moderate (1) (1/1: 100%) Inconclusive 
Diabetes or 
hypothyroid 
+19 Moderate (1) 1/1: 100% 
(0/1: 0%) 
Inconclusive 
Pregnancy or 
injury 
associated CTS 
- 
19
 Moderate (1) 0/1: 0 % Inconclusive 
Arthritis +19 Moderate (1) 1/1: 100% 
(0/1: 0%) 
Inconclusive 
Previous 
fracture or 
sprain 
027 High (1) 0/1: 0 % Inconclusive 
Stenosing +*27 High (1)  (1/1: 100%) Inconclusive 
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flexor 
tenosynovitis 
Mental health 
status 
+*29 Moderate (1) (1/1: 100%) Inconclusive 
Disease 
characteristics  
    
Tinnel’s sign 
positive 
+ 34 Moderate (1) 1/1: 100% 
(0/1: 0%) 
Inconclusive 
Phalen’s sign 
positive 
+*21 Moderate (2) 
 
High (1) 
3/3: 100 % 
(2/3: 67%) 
Inconclusive 
+ 34  
+*27  
Thenar wasting +* 28 Moderate (2) 
 
High (1) 
3/3: 100 % 
(2/3: 67%) 
Inconclusive 
+34  
+*27  
Paraesthesia +*27 High (1) (1/1: 100%) Inconclusive 
Abnormal two-
point 
discrimination 
030 
+*27 
Moderate (1) 
High (1) 
1/2: 50% 
(1/2: 50%) 
Inconclusive 
Semmes 
Weinstein 
monofilament 
testing 
030 Moderate 0/1: 0 % Inconclusive 
Electrophysiolo
gical severity 
+34  
026 
-*
21
 
Moderate (3) 
 
 
2/5: 40% 
(0/5: 0%) 
Inconclusive 
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+31  High (2) 
 -
32
  
Symptom 
severity 
-*
26
 Moderate (2) 
 
High (1) 
1/3: 33% 
(1/3: 33%) 
Inconclusive 
-*
21
 
+*33 
Functional 
severity 
+*29 
-*
26
, 
21
 
033 
Moderate (3) 
 
High (1) 
1/4: 25% 
(1/4: 25%) 
Inconclusive 
CTS category of 
severity19 
+*19 Moderate (1) (1/1: 100%)  
Sensory SF-
MPQ 
+34 Moderate (1) 1/1: 100% 
(0/1: 0%) 
Inconclusive 
Affective SF-
MPQ 
+34 Moderate 1 1/1: 100% 
(0/1: 0%) 
Inconclusive 
SF-36 033 High (1) 0/1: 0 % Inconclusive 
DASH 033 High (1) 0/1: 0 %  
Hi-Ob -*21 Moderate (1) 0/1: 0 % Inconclusive 
Visual analog 
scale 
+34 Moderate (1) 1/1: 100% 
(0/1: 0%) 
Inconclusive 
Laterality: left 
only  
-
19
 Moderate (1) 0/1: 0 % Inconclusive 
Laterality: right 
only 
-*
19
 Moderate (1) 0/1: 0 % Inconclusive 
Laterality: left > -19 Moderate (1) 0/1: 0 % Inconclusive 
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right 
Laterality: right 
> left 
-
19
 Moderate (1) 0/1: 0 % Inconclusive 
Bilateral  +*21 Moderate (2) 
 
High (1) 
2/3: 67% 
(1/3: 33%) 
Inconclusive 
+34 
027 
Grip strength 030 m 
- 
34
 m 
Moderate (2) 0/2: 0% Inconclusive 
Hand stress -*21 Moderate (1) 0/1: 0 % Inconclusive 
Increasing 
symptom 
duration  
+* 28, 21 Moderate (3) 
 
 
High (2) 
5/5: 100% 
(3/5: 60%) 
Inconclusive 
+26  
+*27 
+32  
0 = not significant and direction not provided 
+ = predictive of a negative outcome 
- = not predictive of a negative outcome 
* = statistically significant 
 
SF-MPQ – Short-Form McGill pain questionnaire 
SF-36 – Short-Form 36 
DASH – Disabilities of the arm, shoulder and hand questionnaire 
Hi-Ob – Historical objective scale 
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Figure 1 Study Selection 
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Supplementary Table: Medline Search Strategy   
1. median neuropathy/ or exp carpal tunnel syndrome/ 
2. "carpal tunnel syndrome".mp. [mp=title, abstract, original title, name of substance 
word, subject heading word, keyword heading word, protocol supplementary 
concept, rare disease supplementary concept, unique identifier] 
3. Nerve Compression Syndromes/ 
4. entrapment neuropath*.ti,ab. 
5. exp Median Nerve/ 
6. nerve entrapment*.ti,ab. 
7. Hand/ and Pain/ 
8. Pain/ and Wrist/ 
9. (carpal$ adj3 tunnel$).mp. 
10. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 
11. exp Prognosis/ 
12. exp Disease Progression/ 
13. prognos*.mp. 
14. predict*.mp. 
15. factor*.mp. 
16. risk*.mp. 
17. model*.mp. 
18. evolution.mp. 
19. history.mp. 
20. indicator*.mp. 
21. course.mp. 
22. rule*.mp. 
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23. transition*.mp. 
24. determinant*.mp. 
25. pattern*.mp. 
26. subgroup*.mp. 
27. sub-group*.mp. 
28. screen*.mp. 
29. long-term.mp. 
30. progress*.mp. 
31. modif*.mp. 
32. mediat*.mp. 
33. or/11-32 
34. exp Epidemiologic Studies/ 
35. cohort*.mp. 
36. follow-up.mp. 
37. follow-up.mp. 
38. ("case control" or "case controlled").mp. 
39. retrospective*.mp. 
40. prospective*.mp. 
41. ((patient* or medical) adj3 (record* or review* or histor*)).mp. 
42. longitudinal*.mp. 
43. inception.mp. 
44. observation*.mp. 
45. time series.mp. 
46. outcome*.mp. 
47. or/34-46 
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48. 33 and 47 
59. 10 and 48 
 
